Key result
Liraglutide shows no excess risk of worsening renal function over placebo in HFrEF.
Why the study?
A significant increase in cystatin C with liraglutide in the FIGHT trial raised concern of adverse renal outcomes, prompting this evaluation of worsening renal function.
Does liraglutide increase the risk of worsening renal function in patients with HFrEF and a recent hospitalization for heart failure?
Cohort (n=274)
Double-blind
Double-blind, placebo-controlled (parent trial)
Does liraglutide increase the risk of worsening renal function in patients with HFrEF and a recent hospitalization for heart failure?
Odds Ratio: 1.02 (95% CI 0.62–1.67)
Liraglutide initiation shortly after hospitalization for HFrEF is not associated with an increased risk of worsening renal function, supporting its relative renal safety in this high-risk population.
Supports relative renal safety of liraglutide post-HFrEF hospitalization; leaves open need for prospective renal outcome trials.
BACKGROUND: The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for heart failure to liraglutide versus placebo. While there was no difference in the primary outcome (rank score of time to death, time to rehospitalization for heart failure, and change in NT-proBNP [N-terminal pro-B-type natriuretic peptide]), there was a significant increase in cystatin C among patients randomized to liraglutide raising concern of adverse renal outcomes. We performed a post hoc analysis of FIGHT to investigate whether liraglutide was associated with worsening renal function (WRF). METHODS: The relationship between randomization to liraglutide and WRF was evaluated using logistic regression models. Two hundred seventy-four patients (91%) had complete data to assess for WRF defined as: increase in SCr ≥0.3 mg/dL, or ≥25% decrease in estimated glomerular filtration rate, or an increase in cystatin C ≥0.3 mg/L from baseline to 180-days. RESULTS: Patients with WRF (n=113, 41%), compared with those without, were older, had more comorbidities, and lower utilization of guideline-directed medical treatment. Logistic regression models showed that age and baseline cystatin C levels were associated with WRF. In adjusted models, liraglutide was not associated with excess risk of WRF compared with placebo (odds ratio, 1.02 [95% CI, 0.62-1.67]). There was also no difference in the rank score when WRF was added as a fourth-tier outcome. CONCLUSIONS: Liraglutide was not associated with WRF among patients with HFrEF and a recent hospitalization for heart failure. These data support the relative renal safety profile of liraglutide among patients with HFrEF. Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01800968.
No takes yet. Share an insight, caveat, or question.
Redouane et al. (2020) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) and recent hospitalization (n=274). Liraglutide vs. Placebo was evaluated on Worsening renal function (WRF) defined as increase in SCr ≥0.3 mg/dL, or ≥25% decrease in eGFR, or an increase in cystatin C ≥0.3 mg/L from baseline to 180-days (OR 1.02, 95% CI 0.62-1.67). Liraglutide was not associated with an excess risk of worsening renal function compared with placebo (OR 1.02) among patients with HFrEF and a recent hospitalization.